Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
261.99
-2.70 (-1.02%)
At close: Jul 24, 2026, 4:00 PM EDT
261.40
-0.59 (-0.23%)
After-hours: Jul 24, 2026, 7:55 PM EDT
Natera Employees
Natera had 6,140 employees as of December 31, 2025. The number of employees increased by 1,706 or 38.48% compared to the previous year.
Employees
6,140
Change (1Y)
1,706
Growth (1Y)
38.48%
Revenue / Employee
$407,317
Profits / Employee
-$36,859
Market Cap
37.52B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6,140 | 1,706 | 38.48% |
| Dec 31, 2024 | 4,434 | 1,141 | 34.65% |
| Dec 31, 2023 | 3,293 | 275 | 9.11% |
| Dec 31, 2022 | 3,018 | 348 | 13.03% |
| Dec 31, 2021 | 2,670 | 855 | 47.11% |
| Dec 31, 2020 | 1,815 | 776 | 74.69% |
| Dec 31, 2019 | 1,039 | 64 | 6.56% |
| Dec 31, 2018 | 975 | 82 | 9.18% |
| Dec 31, 2017 | 893 | 41 | 4.81% |
| Dec 31, 2016 | 852 | 136 | 18.99% |
| Dec 31, 2015 | 716 | 42 | 6.23% |
| Dec 31, 2014 | 674 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IQVIA Holdings | 93,000 |
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| ICON Public Limited Company | 40,100 |
| Agilent Technologies | 18,100 |
| Mettler-Toledo International | 18,100 |
| IDEXX Laboratories | 11,000 |
| Illumina | 10,080 |
NTRA News
- 3 days ago - Natera reports results from multicenter study in MCC - TheFly
- 3 days ago - Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study - Business Wire
- 8 days ago - Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera™ Portfolio - Business Wire
- 10 days ago - Natera price target raised to $325 from $280 at TD Cowen - TheFly
- 11 days ago - Natera price target raised to $330 from $285 at Canaccord - TheFly
- 16 days ago - Natera price target raised to $310 from $250 at Morgan Stanley - TheFly
- 16 days ago - Natera announces IVDR certification for Signatera - TheFly
- 16 days ago - Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers - Business Wire